

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6397761
<b>Application Number:</b>	10522529
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	7480
<b>Title of Invention:</b>	Methods of preparing a foam comprising a sclerosing agent
<b>First Named Inventor/Applicant Name:</b>	David Dakin Iorwerth Wright
<b>Customer Number:</b>	22852
<b>Filer:</b>	Brenda Lynn Danek/astrid blakemore
<b>Filer Authorized By:</b>	Brenda Lynn Danek
<b>Attorney Docket Number:</b>	07588.0079
<b>Receipt Date:</b>	05-NOV-2009
<b>Filing Date:</b>	11-AUG-2006
<b>Time Stamp:</b>	15:34:18
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	EP1716871.PDF	2065660 <small>2c5edaf5e8183cc90013c1e1ba95a25ac58a655a</small>	no	45

**Warnings:**

**Information:**

2	Foreign Reference	EP0586875.PDF	376963 74d742472a3c2475d994a020580598931388b6e41	no	6
Warnings:					
Information:					
3	Foreign Reference	EP0564505_AB.PDF	841183 912ed998d02eeb65c4179ba446cf4c6ce05ad58398	no	22
Warnings:					
Information:					
4	Foreign Reference	GB2369996.PDF	956244 e29c5d34c15d98c278c1a099308154bc2ba5cf77cf	no	21
Warnings:					
Information:					
5	Foreign Reference	WO04_047969_AB.PDF	907531 6ad188b75ce886cc457b2b617e7995bdc63278e	no	21
Warnings:					
Information:					
6	Foreign Reference	WO03_013475_AB.PDF	668410 f984273a108c79dc1dc1db523b1b3c1742ee96dc	no	16
Warnings:					
Information:					
7	Foreign Reference	WO02_058834_AB.PDF	1005534 e8b55a5c5d16272a83cd3c5f328073441db7a428	no	21
Warnings:					
Information:					
8	Foreign Reference	WO00_78629.PDF	831512 59ca087b6793536d6c0c18c280737777d634834	no	20
Warnings:					
Information:					
9	Foreign Reference	WO97_13585.PDF	1177959 29029ea2f22522629c13f5811ced3dca9852b20	no	25
Warnings:					
Information:					
10	Foreign Reference	WO96_38180.PDF	1630964 90c9104b605c78b3c43c2e692886b772c49a82	no	35
Warnings:					
Information:					

11	Foreign Reference	WO96_08227_AB.PDF	1261979 766cc323e65c42b08b9d47c0fcd8578fdef117	no	30
Warnings:					
Information:					
12	Foreign Reference	WO93_05819.PDF	2249822 c1e991a48f9590265c4d133a025e1b65c1f96d	no	51
Warnings:					
Information:					
13	Foreign Reference	WO92_11873_AB.PDF	663759 c1c326c4f830908b7c4b4001445a753b4000547bd	no	17
Warnings:					
Information:					
14	NPL Documents	ANON_NewDrugsAustralianPrescriber.PDF	354467 27478b2001c3480226c592cde6d62ca1f1be00cc	no	4
Warnings:					
Information:					
15	NPL Documents	BARRY_AtmosphereWeatherClimate.pdf	261961 6c03d631e1ebab013e5c45d1266c055b03d629f	no	2
Warnings:					
Information:					
16	NPL Documents	CAPRINI_DirectFactorXInhibition.PDF	149456 61a1b654f8ba7f658605c5f0415e0e5d48fdd	no	2
Warnings:					
Information:					
17	NPL Documents	CAPRINI_DVTProphylaxis.PDF	344727 9578d11de9ab9655365e114b622a3813179239	no	4
Warnings:					
Information:					
18	NPL Documents	CAVEZZI_DuplexGuidedSclerotherapy.PDF	1316139 8016a25683813a284b423a1318b40417c721f981a	no	11
Warnings:					
Information:					
19	NPL Documents	ChartofMicrofoamPatentsandApplications.PDF	309365 b0f9d137c402657a31a02b8dc5f8f03e19f3	no	1
Warnings:					
Information:					

20	NPL Documents	CHO_CarbonDioxideAngiography.PDF	1372863 ccc631961bc4d8b2aa75a628f5c62651ccc29d	no	17
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	COMEROTA_ManagementOfAcuteDVT.PDF	174759 c731c3f827ed1b4a23abae01ba11ed4c6c1799	no	5
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	ELIAS_IsThereaLeak.PDF	871920 1c779664471b5819b4c0f5c49006c4bc0c5e	no	12
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	FRONEK_TreatmentofSmallVeins.PDF	322229 823a896177c86c41a3ed38196511cc01b5a69	no	7
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	FRULLINI_SclerosingFoam.PDF	1751548 b80211b44e785830aef740c3415c261aeb7013a	no	14
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	GARCIA-MINGO_FoamMedicalSystemA New.PDF	488873 1c00012b0c62385d7081aef9f4669cac312238	no	6
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	GIBSON_ProprietyPolidocanolEndovenousMicrofoam.PDF	609961 f6b045c5e47d2902b184b08067cabc91ce9Ed	no	4
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	GILLET_SideEffectsandComplications.PDF	135147 55a8b2b9a6a3a8d9f0281aeb06091e799661b3c7	no	4
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	GUEX_TheFrenchPolidocanolRegistry.PDF	477979 802654f213531aefc5e08f25b38f922a0cd83	no	4
<b>Warnings:</b>					
<b>Information:</b>					

29	NPL Documents	HARPER_AdvancesinTherapyof rVenous.PDF	360757 e347a2771b80011247b6e458c95f53b5 36b	no	8
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	HENRIET_HistoryofFoam.PDF	261678 6d5d8d8218ca875634a72bd198e6128c08 88887	no	6
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	HILL_ComparisonofSclerosantF oam.PDF	223931 7a61a1d83c1d903532a4781c4d7E1961c48 R6cDe	no	6
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	HOHLER_ComparisonBetween ThreeDimensional.PDF	265487 7c792b7b9bdc00bc94996ca5eda15c8eb 6da17	no	6
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	KING_HowSafeIsHigh.PDF	157029 bd70362c67ab447c3607b6428f5f98213 1d805	no	4
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	KRUSCH_InsuranceandCoding forPhlebology.PDF	338216 1ae9ed694c8dd47d6df021cc8801619115 d052	no	10
<b>Warnings:</b>					
<b>Information:</b>					
35	NPL Documents	LUKE_TheManagementofRecur rentVaricose.PDF	352923 81b68ba9c4d413bb67d4e9781dd201d623 c8ec3	no	6
<b>Warnings:</b>					
<b>Information:</b>					
36	NPL Documents	MaterialSafetyDatasheet.PDF	229755 8c072a093c16b4b4c18786baa942130d1 d6027	no	10
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	MEISSNER_PelvicVeinsandVasc ular.PDF	1254727 c4eb67218a05c6b367a342a24fb31e09f3 d7d6b	no	13
<b>Warnings:</b>					
<b>Information:</b>					

38	NPL Documents	MORRISON_FoamSafetyStudies.PDF	329701 b056c68d4dc3ca34d1b535a43ac28a45b5a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	MORRISON_StrategiesforPreventingtheBig.PDF	408195 000ba449465557be9783bdc70077191a9f8298b	no	9
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	NEUHARDT_EmboliDetectionintheMCAConcurrent.PDF	202714 d4c071908be0ca3b6dc65a4f12c09e300730b730	no	7
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	PITTALUGAP_TheComplexCase.PDF	256973 c099198c990dbf6a5752e5ca7edaf6f58f12	no	5
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	PROEBSTLE_OneandTwoYears.PDF	63806 c593449c88a43115d10817e053a1161727b5012	no	3
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	RABE_PolidocanolSodiumTetradecylSulfate.PDF	161524 628b12616ef2a0567298b6c94bdc63bee266da1	no	4
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	RATHBUN_VenousThromboembolismTheProblem.PDF	127429 4a921425a13a095f0369568d0ae4ab3cfa209	no	4
<b>Warnings:</b>					
<b>Information:</b>					
45	NPL Documents	ROBERTSON_AStudyoftheLocal.PDF	308747 e7a2baeca1bd0998b1a06cdd77a170a2baa3399a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	SADOUN_SclerosingFoamMaterialandMethods.PDF	520262 f1bf63e04a095f0e5a18b79afdc261a2593b07e	no	8
<b>Warnings:</b>					
<b>Information:</b>					

47	NPL Documents	SCHLIEPHAKE_ANewStandardizedDigital.PDF	225578 886d24debf5c5239c86a5cc01019c302c0b0a7	no	6
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	SCHUL_CompressionTherapy_vs_Sclerotherapy.PDF	95792 d6498517bd176c1076c4c64d722ba8fc62bd47f5a	no	4
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	SCHUL_InsuranceDenials.PDF	110272 c59415025c6ef4f132c76781328a03264f789c43c	no	4
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	SICA_UltrasoundAppearanceVsSclerosing.PDF	286328 62f1878039d26c8b8fc1fec301ef7b23623749b4	no	4
<b>Warnings:</b>					
<b>Information:</b>					
51	NPL Documents	SLUTSKY_SclerotherapyComplicationsMatting.PDF	150164 4c96193303290bf75ae195cd5877e80881c5b6952	no	4
<b>Warnings:</b>					
<b>Information:</b>					
52	Information Disclosure Statement (IDS) Filed (SB/08)	STOUGHTON_BasicSclerotherapy.PDF	788049 58d36a494d57cab93235a5d33c541be417d3d65	no	14
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
53	NPL Documents	TESSARI_TheTurbillonTurbulence.PDF	373956 1ec851a2728f5db9f9182c68994846a0bb304310	no	5
<b>Warnings:</b>					
<b>Information:</b>					
54	NPL Documents	WAKEFIELD_DiagnosisandManagementofPE.PDF	274744 4d066d17844c2816c7ab74bc1026a0d01a38c43da	no	8
<b>Warnings:</b>					
<b>Information:</b>					
55	NPL Documents	WAKEFIELD_NewAnticoagulant.s.PDF	385317 007918999Ad2dbbc75adbc42258251948c6404	no	8

<b>Warnings:</b>					
<b>Information:</b>					
56	NPL Documents	WRIGHT_ASingleCenterPilot. PDF	310018 <small>3d8bb8e8dc298137e7f4b2c6d8972c18554c5 9012e</small>	no	3
<b>Warnings:</b>					
<b>Information:</b>					
57	NPL Documents	WRIGHT_TheVarisolveTrialWill. PDF	2151002 <small>d8c4f8668d8f847df661cc7a3c38d4430d5 b56d1</small>	no	38
<b>Warnings:</b>					
<b>Information:</b>					
58	NPL Documents	GermanNullityActionDecision. PDF	827394 <small>e5811b1b13e14d809f5d8617002ab1ae0c af718</small>	no	20
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			35381382		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>          If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>          If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>          If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					